The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis

<b>Background:</b> Anti-Vascular Endothelial Growth Factor (VEGF) therapy is an effective therapy for improving and stabilizing the vision of patients with neovascular age-related macular degeneration (nAMD). However, the treatment requirements, particularly the number of intraocular inj...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Grün, Kai Rothaus, Martin Ziegler, Clemens Lange, Albrecht Lommatzsch, Henrik Faatz
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/15/8/982
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850143846272335872
author Michael Grün
Kai Rothaus
Martin Ziegler
Clemens Lange
Albrecht Lommatzsch
Henrik Faatz
author_facet Michael Grün
Kai Rothaus
Martin Ziegler
Clemens Lange
Albrecht Lommatzsch
Henrik Faatz
author_sort Michael Grün
collection DOAJ
description <b>Background:</b> Anti-Vascular Endothelial Growth Factor (VEGF) therapy is an effective therapy for improving and stabilizing the vision of patients with neovascular age-related macular degeneration (nAMD). However, the treatment requirements, particularly the number of intraocular injections, can vary significantly among patients. This study aimed to analyze the vascular characteristics of macular neovascularizations (MNVs) to identify potential biomarkers that could predict the required injection frequency throughout the disease course. <b>Methods:</b> In all patients, the initial diagnosis of nAMD was confirmed using optic coherence tomography (OCT), fluorescein angiography, and OCT angiography (OCTA). MNVs detected using OCTA were subjected to quantitative vascular analysis of their area, total vascular length (sumL), fractal dimension (FD), and flow density. These results were then correlated with the number of intravitreal anti-VEGF treatments administered during the first 3 years of treatment. Additionally, the relationship between the parameters and visual acuity progression was analyzed. <b>Results:</b> A total of 68 treatment-naïve eyes were included in the study, comprising 31 eyes with type 1 MNV, 19 eyes with type 2 MNV, and 18 eyes with type 3 MNV. The average MNV area at baseline was 1.11 mm<sup>2</sup> ± 1.18 mm<sup>2</sup>, the mean total vascular length was 12.95 mm ± 14.24 mm, the mean fractal dimension was 1.26 ± 0.14, and the mean flow density was 41.19 ± 5.87. On average, patients in our cohort received 19.8 ± 8.5 intravitreal injections (IVIs). A significant correlation was found between the number of administered IVIs in the first 3 treatment years and the MNV area (<i>p</i> < 0.005), sumL (<i>p</i> < 0.005), and FD (<i>p</i> < 0.05), while no correlation was found with flow density. Additionally, there was no significant association between MNV type and treatment requirements, nor between MNV vascular architecture and visual acuity progression. <b>Conclusions:</b> The results suggest that the specific vascular structure of untreated MNV may serve as a predictor of long-term treatment demand. With the emergence of new drug classes and advancements in imaging techniques, these parameters could offer valuable insights for forecasting treatment requirements.
format Article
id doaj-art-a1d4b9994e004374bfc4fd0dc192e41b
institution OA Journals
issn 2075-4418
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj-art-a1d4b9994e004374bfc4fd0dc192e41b2025-08-20T02:28:33ZengMDPI AGDiagnostics2075-44182025-04-0115898210.3390/diagnostics15080982The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal AnalysisMichael Grün0Kai Rothaus1Martin Ziegler2Clemens Lange3Albrecht Lommatzsch4Henrik Faatz5Department of Ophthalmology at St. Franziskus Hospital, 48145 Münster, GermanyDepartment of Ophthalmology at St. Franziskus Hospital, 48145 Münster, GermanyDepartment of Ophthalmology at St. Franziskus Hospital, 48145 Münster, GermanyDepartment of Ophthalmology at St. Franziskus Hospital, 48145 Münster, GermanyDepartment of Ophthalmology at St. Franziskus Hospital, 48145 Münster, GermanyDepartment of Ophthalmology at St. Franziskus Hospital, 48145 Münster, Germany<b>Background:</b> Anti-Vascular Endothelial Growth Factor (VEGF) therapy is an effective therapy for improving and stabilizing the vision of patients with neovascular age-related macular degeneration (nAMD). However, the treatment requirements, particularly the number of intraocular injections, can vary significantly among patients. This study aimed to analyze the vascular characteristics of macular neovascularizations (MNVs) to identify potential biomarkers that could predict the required injection frequency throughout the disease course. <b>Methods:</b> In all patients, the initial diagnosis of nAMD was confirmed using optic coherence tomography (OCT), fluorescein angiography, and OCT angiography (OCTA). MNVs detected using OCTA were subjected to quantitative vascular analysis of their area, total vascular length (sumL), fractal dimension (FD), and flow density. These results were then correlated with the number of intravitreal anti-VEGF treatments administered during the first 3 years of treatment. Additionally, the relationship between the parameters and visual acuity progression was analyzed. <b>Results:</b> A total of 68 treatment-naïve eyes were included in the study, comprising 31 eyes with type 1 MNV, 19 eyes with type 2 MNV, and 18 eyes with type 3 MNV. The average MNV area at baseline was 1.11 mm<sup>2</sup> ± 1.18 mm<sup>2</sup>, the mean total vascular length was 12.95 mm ± 14.24 mm, the mean fractal dimension was 1.26 ± 0.14, and the mean flow density was 41.19 ± 5.87. On average, patients in our cohort received 19.8 ± 8.5 intravitreal injections (IVIs). A significant correlation was found between the number of administered IVIs in the first 3 treatment years and the MNV area (<i>p</i> < 0.005), sumL (<i>p</i> < 0.005), and FD (<i>p</i> < 0.05), while no correlation was found with flow density. Additionally, there was no significant association between MNV type and treatment requirements, nor between MNV vascular architecture and visual acuity progression. <b>Conclusions:</b> The results suggest that the specific vascular structure of untreated MNV may serve as a predictor of long-term treatment demand. With the emergence of new drug classes and advancements in imaging techniques, these parameters could offer valuable insights for forecasting treatment requirements.https://www.mdpi.com/2075-4418/15/8/982macular neovascularizationimagingage-related macular degenerationOCT angiographychoroidal neovascularizationanti-VEGF therapy
spellingShingle Michael Grün
Kai Rothaus
Martin Ziegler
Clemens Lange
Albrecht Lommatzsch
Henrik Faatz
The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
Diagnostics
macular neovascularization
imaging
age-related macular degeneration
OCT angiography
choroidal neovascularization
anti-VEGF therapy
title The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
title_full The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
title_fullStr The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
title_full_unstemmed The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
title_short The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
title_sort vascular architecture of macular neovascularization in age related macular degeneration as a predictor of therapy requirements a 3 year longitudinal analysis
topic macular neovascularization
imaging
age-related macular degeneration
OCT angiography
choroidal neovascularization
anti-VEGF therapy
url https://www.mdpi.com/2075-4418/15/8/982
work_keys_str_mv AT michaelgrun thevasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT kairothaus thevasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT martinziegler thevasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT clemenslange thevasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT albrechtlommatzsch thevasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT henrikfaatz thevasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT michaelgrun vasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT kairothaus vasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT martinziegler vasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT clemenslange vasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT albrechtlommatzsch vasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis
AT henrikfaatz vasculararchitectureofmacularneovascularizationinagerelatedmaculardegenerationasapredictoroftherapyrequirementsa3yearlongitudinalanalysis